| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013285099 |
| P356 | DOI | 10.1007/S00018-009-0246-5 |
| P698 | PubMed publication ID | 20063037 |
| P50 | author | Antonio Paolo Beltrami | Q39189732 |
| Paola Secchiero | Q39507349 | ||
| Giorgio Zauli | Q39507392 | ||
| Federica Corallini | Q114516464 | ||
| P2093 | author name string | Roberto Ferrari | |
| Carlo Alberto Beltrami | |||
| Daniela Cesselli | |||
| Elisa Puppato | |||
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review | Q33359478 | ||
| Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction | Q33409850 | ||
| The role of tumor necrosis factor in the pathophysiology of heart failure | Q33862430 | ||
| An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction | Q35569854 | ||
| The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology | Q36496323 | ||
| The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice | Q37071096 | ||
| Role of full-length osteoprotegerin in tumor cell biology | Q37326459 | ||
| Stem cell engineering for treatment of heart diseases: potentials and challenges | Q37351399 | ||
| MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. | Q40188347 | ||
| Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease | Q43865169 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells | Q44370220 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. | Q44698226 | ||
| Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction | Q45149635 | ||
| Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. | Q46670294 | ||
| Factors influencing spontaneous mobilization of CD34+ and CD133+ progenitor cells after myocardial infarction | Q46921519 | ||
| Prognostic value of apoptosis markers in advanced heart failure patients. | Q48765555 | ||
| Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). | Q51767101 | ||
| TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. | Q51776448 | ||
| Improvement in cardiac function after bone marrow cell thearpy is associated with an increase in myocardial inflammation. | Q53438967 | ||
| Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. | Q54574005 | ||
| Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction | Q57484933 | ||
| Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction | Q57589498 | ||
| Excessive Tumor Necrosis Factor Activation After Infarction Contributes to Susceptibility of Myocardial Rupture and Left Ventricular Dysfunction | Q58047222 | ||
| Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice | Q59225243 | ||
| TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release | Q59225302 | ||
| TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells | Q59225352 | ||
| Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells | Q59225404 | ||
| Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart | Q71102878 | ||
| Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology | Q71814699 | ||
| Increased osteoprotegerin serum levels in men with coronary artery disease | Q73106368 | ||
| Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease | Q74711101 | ||
| Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload | Q79665023 | ||
| Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone | Q79697473 | ||
| Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes | Q79793005 | ||
| Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells | Q79912666 | ||
| The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities | Q80065296 | ||
| Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction | Q80319873 | ||
| Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes | Q80665048 | ||
| Differential increase of CD34, KDR/CD34, CD133/CD34 and CD117/CD34 positive cells in peripheral blood of patients with acute myocardial infarction | Q80738488 | ||
| Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure | Q81730161 | ||
| Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction | Q82917837 | ||
| Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease | Q84077133 | ||
| P433 | issue | 8 | |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| TNF | Q18032037 | ||
| P304 | page(s) | 1307-1314 | |
| P577 | publication date | 2010-01-09 | |
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. | |
| P478 | volume | 67 |
| Q38067301 | Application of Chinese herbal medicines to revitalize adult stem cells for tissue regeneration. |
| Q35070554 | Cell-based therapies for diabetic complications |
| Q30476872 | Indirect low-intensity ultrasonic stimulation for tissue engineering |
| Q46044549 | LIGHT regulates the adipogenic differentiation of mesenchymal stem cells |
| Q37194115 | Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy |
| Q35128063 | Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation |
| Q37997644 | TNF revisited: osteoprotegerin and TNF-related molecules in heart failure |
| Q36836344 | The birth of 'regenerative pharmacology': a clinical perspective |
Search more.